Cargando…

Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma

INTRODUCTION: Combined anti‐cytotoxic‐T‐lymphocyte antigen 4 and programmed cell death 1 blockade induced high rates of immune‐related adverse events in patients with renal cell carcinoma. However, the safety of reinitiating anti‐programmed cell death 1 monotherapy for patients who discontinued comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Maegawa, Yoko, Kato, Taigo, Fukuhara, Shinichiro, Kiuchi, Hiroshi, Imamura, Ryoichi, Uemura, Motohide, Nonomura, Norio, Fujita, Kazutoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469840/
https://www.ncbi.nlm.nih.gov/pubmed/32914066
http://dx.doi.org/10.1002/iju5.12173
_version_ 1783578476308070400
author Maegawa, Yoko
Kato, Taigo
Fukuhara, Shinichiro
Kiuchi, Hiroshi
Imamura, Ryoichi
Uemura, Motohide
Nonomura, Norio
Fujita, Kazutoshi
author_facet Maegawa, Yoko
Kato, Taigo
Fukuhara, Shinichiro
Kiuchi, Hiroshi
Imamura, Ryoichi
Uemura, Motohide
Nonomura, Norio
Fujita, Kazutoshi
author_sort Maegawa, Yoko
collection PubMed
description INTRODUCTION: Combined anti‐cytotoxic‐T‐lymphocyte antigen 4 and programmed cell death 1 blockade induced high rates of immune‐related adverse events in patients with renal cell carcinoma. However, the safety of reinitiating anti‐programmed cell death 1 monotherapy for patients who discontinued combination therapy due to immune‐related adverse events is largely unknown. CASE PRESENTATION: We report the case of 74‐year‐old man who received combination therapy with anti‐cytotoxic‐T‐lymphocyte antigen 4 and programmed cell death 1 inhibitors for advanced renal cell carcinoma. After three cycles of combination therapy, he complained severe immune‐related adverse events including grade 3 nausea and anorexia, and grade 3 diarrhea, leading to discontinuation of the therapy. He started readministration of anti‐programmed cell death 1 monotherapy at 41 weeks after discontinuation due to the new lung metastatic lesion. Importantly, he experienced only grade 1 diarrhea, which can be controlled with prednisolone. CONCLUSION: The readministration of anti‐programmed cell death 1 monotherapy with close monitoring can be an acceptable treatment even after discontinuation of combination therapy.
format Online
Article
Text
id pubmed-7469840
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74698402020-09-09 Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma Maegawa, Yoko Kato, Taigo Fukuhara, Shinichiro Kiuchi, Hiroshi Imamura, Ryoichi Uemura, Motohide Nonomura, Norio Fujita, Kazutoshi IJU Case Rep Case Report INTRODUCTION: Combined anti‐cytotoxic‐T‐lymphocyte antigen 4 and programmed cell death 1 blockade induced high rates of immune‐related adverse events in patients with renal cell carcinoma. However, the safety of reinitiating anti‐programmed cell death 1 monotherapy for patients who discontinued combination therapy due to immune‐related adverse events is largely unknown. CASE PRESENTATION: We report the case of 74‐year‐old man who received combination therapy with anti‐cytotoxic‐T‐lymphocyte antigen 4 and programmed cell death 1 inhibitors for advanced renal cell carcinoma. After three cycles of combination therapy, he complained severe immune‐related adverse events including grade 3 nausea and anorexia, and grade 3 diarrhea, leading to discontinuation of the therapy. He started readministration of anti‐programmed cell death 1 monotherapy at 41 weeks after discontinuation due to the new lung metastatic lesion. Importantly, he experienced only grade 1 diarrhea, which can be controlled with prednisolone. CONCLUSION: The readministration of anti‐programmed cell death 1 monotherapy with close monitoring can be an acceptable treatment even after discontinuation of combination therapy. John Wiley and Sons Inc. 2020-06-25 /pmc/articles/PMC7469840/ /pubmed/32914066 http://dx.doi.org/10.1002/iju5.12173 Text en © 2020 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Maegawa, Yoko
Kato, Taigo
Fukuhara, Shinichiro
Kiuchi, Hiroshi
Imamura, Ryoichi
Uemura, Motohide
Nonomura, Norio
Fujita, Kazutoshi
Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
title Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
title_full Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
title_fullStr Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
title_full_unstemmed Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
title_short Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
title_sort resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469840/
https://www.ncbi.nlm.nih.gov/pubmed/32914066
http://dx.doi.org/10.1002/iju5.12173
work_keys_str_mv AT maegawayoko resumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma
AT katotaigo resumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma
AT fukuharashinichiro resumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma
AT kiuchihiroshi resumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma
AT imamuraryoichi resumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma
AT uemuramotohide resumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma
AT nonomuranorio resumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma
AT fujitakazutoshi resumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma